ZBIO Zenas BioPharma, Inc. Common Stock
XNAS
27.24
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
ZBIO
$27.24
—
Key stats
$27.24
- 52-Week Range
- $13.50 – $44.60
- YTD
- -21.04%
- IV Rank (30D)
- 64.15
- Straddle Price
- $6.65
- P/C Vol Ratio
- 0.50
- Market Cap
- $1.8B
- Open
- $27.18
- Day Range
- $26.68 – $28.18
- Volume
- 371,648
- Prev Close
- $26.87
Fair Value
MODEL: LONG
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 5.13% |
| Beta vs SPY | 0.61 |
| Cost of Equity (CAPM) | 8.17% (VRP-adj) |
| WACC | 7.71% |
| Volatility Risk Premium | +129.2pp (IV − HV30) |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +3.0% |
| DCF Horizon | 5 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.03 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $-0.2B |
| Return on Equity (TTM) | -196.0% |
| Book / Price | 17.2% |
| Gross Margin (TTM) | 100.0% |
| FCF Margin (TTM) | -22597.4% |
| Debt / Equity | 1.20 |
| Quality Score | 1/6 — cyclical/struggling (5y DCF) |
| SMA 50 | $29.76 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $26.93 |
| Bollinger Width / SMA20 | 62.0% (drives anchor stability) |
| Net Debt | $0.1B |
| Market Cap | $1B |
Peers used for multiples: ALKS, CELC, CGON, COGT, KYMR, MIRM, SYRE, XENE
60-Day Conviction
31%
20-Day Fair Value
≈ by Nov 24, 2026
$27.30
α +0.2%
rank 42%
conviction
14%
40-Day Fair Value
≈ by Dec 23, 2026
$27.44
α +0.8%
rank 46%
conviction
25%
60-Day Fair Value
≈ by Jan 21, 2027
$27.48
α +0.9%
rank 31%
conviction
31%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | |
| Peer EV/EBITDA | n/a | 0% | |
| Peer P/B | $26.56 | 29% | median 5.8× · 6 peers |
| Peer P/S | $0.93 | 29% | median 48.3× · 4 peers |
| Market Anchor (SMA50) | $29.76 | 0% | stability 0% (BB-width) |
| Options Expected (B-L 30d) | $26.43 | 41% | 11 strikes · skew +0.18 |
As of 2026-10-26 · updated
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $1.8B
- Employees
- 167
- List Date
- 2024-09-13
- CIK
- 0001953926
- Headquarters
- Waltham, MA
- Homepage
- https://www.zenasbio.com
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company manages its operations on a consolidated basis as a single reportable segment focused on the research, development and commercialization of transformative immunology-based therapies.
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '24 | '25 | '26 | Avg |
|---|---|---|---|---|
| Jan | -- | -10.99% | -46.75% | -28.87% |
| Feb | -- | -5.40% | 45.18% | 19.89% |
| Mar | -- | 18.98% | -23.51% | -2.27% |
| Apr | -- | 52.37% | -5.11% | 23.63% |
| May | -- | -17.65% | -4.96% | -11.30% |
| Jun | -- | -3.68% | 39.68% | 18.00% |
| Jul | -- | 71.88% | 11.97% | 41.92% |
| Aug | -- | 3.83% | 3.82% | 3.83% |
| Sep | -6.78% | 26.71% | -15.67% | 1.42% |
| Oct | 24.62% | 41.27% | -2.51%* | 21.13% |
| Nov | -43.77% | 23.94% | -- | -9.92% |
| Dec | -26.88% | -2.05% | -- | -14.46% |
| Total | -52.24% | 369.58% | -28.81% | 96.18% |
* Only 3 year(s) of data available.
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $26.92
SMA 50: $29.72
SMA 200: $24.79
Current: $27.24
EMA 12: $27.11
EMA 26: $27.76
MACD: -0.6421 | Signal: 0.2966
BEARISH
ADX (14): 19.79
RANGE
+DI: 16.38
−DI: 19.63
Momentum Oscillators
RSI (14): 47.41
NEUTRAL
Stoch %K: 58.60
Stoch %D: 64.69
Williams %R: -45.19
Volume & Volatility
BB Upper: $29.16
BB Lower: $24.68
NEUTRAL
OBV: 14,629,786
Vol SMA 20: 613,394
Vol ROC: -38.32%
ATR: $1.88
True Range: $1.50
HV 20: 60.3%
HV 30: 63.8%
HV 60: 54.9%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-28T00:00:00 – 2026-10-26T00:00:00
AI Analysis
LLM Stock Analysis Report
Executive Summary
Overall Assessment: BULLISH (confidence level: 8/10)
Key Drivers:
- Strong momentum signals from MACD and RSI
- Positive news sentiment surrounding recent trial results and financial performance
- Potential for upside from recent IPO and convertible notes offering
Primary Risks:
- High volatility and potential for sharp price movements
- Market sentiment may shift if new negative information emerges
- Risk of a significant correction if IV premium is not justified by actual market movement
Investment Thesis: Zenas BioPharma (ZBIO) has strong momentum signals, positive news sentiment, and favorable risk-reward characteristics. The stock's recent IPO and convertible notes offering provide potential for upside, but high volatility and market risks remain a concern.
Recent News Sentiment Impact: Positive news headlines have driven the stock's price higher, with investors reacting favorably to trial results and financial performance.
Technical Analysis
Trend Direction:
- Short-term (1-4 weeks): Bullish
- Medium-term (1-3 months): Bullish
- Long-term (3-12 months): Bullish
Support/Resistance Levels: Key price levels from moving averages and technical patterns include:
- SMA 20: $23.67 (support)
- SMA 50: $20.76 (support)
- Upper Bollinger Band: $31.70 (resistance)
Momentum Signals:
- RSI interpretation: Neutral (69.90)
- MACD signal: Bullish
- Bollinger Bands position: Squeeze
Volume Analysis: Volume trends and institutional interest signals include:
- Volume SMA 20: 1126307.00 (neutral)
- On-Balance Volume (OBV): 15773927.53 (bullish)
- Volume Rate of Change: -39.67% (bearish)
News & Sentiment Analysis
Recent Headlines Summary: Positive news headlines have driven the stock's price higher, with investors reacting favorably to trial results and financial performance.
Sentiment Assessment: Aggregate news sentiment is POSITIVE.
Catalyst Identification: Upcoming events include earnings announcements and potential regulatory approvals for new treatments.
Market Narrative: News sentiment aligns with strong technical signals, supporting a bullish narrative.
Risk & Volatility Assessment
Beta Interpretation: High risk relative to market (beta > 1.06).
Volatility Regime: Current volatility is above historical average levels.
Options Market Signals:
- IV rank: Low (7.0%)
- Put/call ratios: Bullish
- Unusual activity: None notable
Downside Protection: Support levels and risk management considerations include:
- SMA 20: $23.67 (support)
- Volume SMA 20: 1126307.00 (neutral)
Market Context & Positioning
Sector Performance: Relative strength vs sector/market is positive.
Institutional Activity: Institutional interest signals are neutral to bullish.
Correlation Analysis: Correlation with market is moderate (R-squared interpretation).
Relative Valuation: Position within trading range is above average, suggesting potential for further upside.
Key Levels & Action Items
Critical Price Levels:
- SMA 20: $23.67 (support)
- Upper Bollinger Band: $31.70 (resistance)
Breakout/Breakdown Levels:
- No notable levels in the near term
Time-Sensitive Catalysts:
- Earnings announcements and potential regulatory approvals for new treatments
Risk Management:
- Stop-loss levels: Consider setting stop-loss at SMA 20 or lower
- Position sizing considerations: Use a position size that aligns with risk tolerance and market conditions
By analyzing Zenas BioPharma's technical indicators, recent news headlines, and risk metrics, the overall assessment is BULLISH. However, high volatility and potential for sharp price movements remain a concern. The stock has strong momentum signals, positive news sentiment, and favorable risk-reward characteristics. The recent IPO and convertible notes offering provide potential for upside, but investors should closely monitor market conditions and adjust their positions accordingly.
Generated
News
All ZBIO news →
Earnings History
4 of 6 under expected move
Avg Expected Move
16.98%
Avg Actual Move
11.19%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2025-08-12 | After-Close | 21.07% | 5.09% | 0.24x | Within |
| 2025-11-12 | After-Close | 10.13% | 0.39% | 0.04x | Within |
| 2026-01-05 | Pre-Market | 40.00% | 51.86% | 1.30x | Exceeded |
| 2026-03-16 | After-Close | 13.78% | 1.08% | 0.08x | Within |
| 2026-05-13 | After-Close | 5.14% | 5.17% | 1.01x | Exceeded |
| 2026-08-11 | After-Close | 11.79% | 3.55% | 0.30x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
ZBIO Options Activity & IV Rank
ZBIO IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 105.9%
7-DTE IV: —
Expected Move: $6.65
7-DTE Move: $6.65
Days to Exp: 25 (2026-11-20)
Options Flow
Call Volume: 6
Put Volume: 3
P/C Volume: 0.5
BULLISH
Call OI: 14
Put OI: 1
P/C OI: 0.071
Total OI: 15
ATM Options Pricing
ATM Call: $4.15
ATM Put: $2.50
Call %: 15.2%
Put %: 9.2%
Chain Summary
Chain Volume: 250
Chain OI: 8,287
Last Updated: 10/26/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
HIGH γ vs HISTORY
Estimated net dealer gamma is at the 81st percentile of this name's own daily history, near the high end of its range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
81%
vs own history
GEX tilt
+0.91
OI-weighted, today
Vanna tilt
+0.72
δ-sensitivity to IV
Charm tilt
-0.80
δ-decay vs time
Vanna tilt +0.72: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.80: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 5 ATM contracts, 0k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
as of Oct 26 · No data
30 DTE / 10d
—
—
pts
EXTREME
as of Oct 26 · ATM 116.8% / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)64.2MediumOct 26
Straddle Price (30 DTE)$6.65Oct 26
Beta Analysis
Risk Metrics
Beta: 0.7086
Alpha: 61.73%
Correlation: 0.0891
R-Squared: 0.8%
Stock Volatility: 101.3%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Low volatility - stock moves less than market
Low volatility - stock moves less than market
Beta & Alpha Over Time
ZBIO Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 53,497,737 (as of 2026-06-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
4 filers$7.57M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $5.74M | 75.80% | 2026-06-30 |
| 2 | Jane Street Group, LLC Custodian | $989.82K | 13.07% | 2026-06-30 |
| 3 | Citadel Advisors LLC Custodian | $784.24K | 10.36% | 2026-06-30 |
| 4 | Simplex Trading, LLC Custodian | $58.37K | 0.77% | 2026-06-30 |
2 filers$487.30K notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $479.68K | 98.44% | 2026-06-30 |
| 2 | Simplex Trading, LLC Custodian | $7.61K | 1.56% | 2026-06-30 |
ZBIO Insider Trading (Form 4)
Latest: 2026-09-02Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-09-02 | Christy J. Oliger | Director | Grant (A) | +37,000 opt | — | EDGAR | |
| 2026-06-17 | Patrick G Enright | Director | Grant (A) | +18,500 opt | — | EDGAR | |
| 2026-06-17 | Lisa von Moltke | See Remarks | Grant (A) | +150,000 opt | — | EDGAR | |
| 2026-06-17 | Joseph L Farmer | See Remarks | Award (A) | +974 | $13.35 | $13.0K | EDGAR |
| 2026-06-17 | Leon O Moulder Jr | See Remarks | Grant (A) | +500,000 opt | — | EDGAR | |
| 2026-06-17 | Hongbo Lu | Director | Grant (A) | +18,500 opt | — | EDGAR | |
| 2026-06-17 | Patricia L Allen | Director | Grant (A) | +18,500 opt | — | EDGAR | |
| 2026-06-17 | John J Orloff | Director | Grant (A) | +18,500 opt | — | EDGAR | |
| 2026-06-17 | Jennifer A. Fox | See Remarks | Award (A) | +1,592 | $13.35 | $21.3K | EDGAR |
| 2026-06-17 | Jason Raleigh Nunn | Director | Grant (A) | +18,500 opt | — | EDGAR | |
| 2026-06-17 | James P Boylan | Director | Grant (A) | +18,500 opt | — | EDGAR | |
| 2026-05-18 | Leon O Moulder Jr | Chief Executive Officer | Buy (P) | +60,000 | $16.88 | $1.01M | EDGAR |
| 2026-04-29 | Leon O Moulder Jr | Chief Executive Officer | Buy (P) | +60,000 | $17.79 | $1.07M | EDGAR |
| 2026-04-02 | Hongbo Lu | Director | Buy (P) | +3,768 | $18.63 | $70.2K | EDGAR |
| 2026-04-01 | Fairmount Healthcare Fund II L.P. | Director | Buy (P) | +600,000 | $20.00 | $12.00M | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
ZBIO Insider Holdings
11 insiders · @ $27.24
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Fairmount Healthcare Fund II L.P. | Director | 2,359,025 | $64.26M | $32.40M | 2 | 2026-04-01 |
| 2 | Peter Evan Harwin | Director | 2,209,025 | $60.17M | $24.03M | 2 | 2025-10-09 |
| 3 | Patrick G Enright | Director | 1,844,659 | $50.25M | $9.73M | 4 | 2026-06-17 |
| 4 | Jason Raleigh Nunn | Director | 1,173,395 | $31.96M | $16.20M | 4 | 2026-06-17 |
| 5 | SR ONE CAPITAL MANAGEMENT, LLC | 10%+ Owner | 1,173,395 | $31.96M | $4.80M | 1 | 2025-10-14 |
| 6 | Leon O Moulder Jr | See Remarks | 520,083 | $14.17M | $6.91M | 13 | 2026-06-17 |
| 7 | Hongbo Lu | Director | 426,736 | $11.62M | $7.65M | 7 | 2026-06-17 |
| 8 | Patricia L Allen | Director | 19,860 | $541.0K | $499.7K | 4 | 2026-06-17 |
| 9 | Ting Xiao | Director | 10,000 | $272.4K | $155.2K | 3 | 2025-04-28 |
| 10 | Jennifer A. Fox | See Remarks | 1,592 | $43.4K | $0 | 4 | 2026-06-17 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
ZBIO Board & Officers
As of SEC filings through Sep 8, 2026Directors 11
- Fairmount Funds Management LLC (entity) · since Sep 12, 2024
- Fairmount Healthcare Fund II L.P. (entity) · since Sep 12, 2024
- Hongbo Lu · since Sep 12, 2024
- James P Boylan · since Sep 12, 2024
- Jason Raleigh Nunn · since Sep 12, 2024
- John J Orloff · since Sep 12, 2024
- Leon O Moulder Jr · since Sep 12, 2024
- Patricia L Allen · since Sep 12, 2024
- Patrick G Enright · since Sep 12, 2024
- Peter Evan Harwin · since Sep 12, 2024
- Christy J. Oliger · since Sep 1, 2026
Officers 5
- Leon O Moulder Jr · Chief Executive Officer · since Sep 12, 2024
- Joseph L Farmer · President and Chief Operating Officer · since Sep 12, 2024
- Jennifer A. Fox · Chief Business Officer and Chief Financial Officer · since Sep 12, 2024
- Orlando Oliveira · Chief Commercial Officer · since Sep 12, 2024
- Lisa von Moltke · Head of Research and Development and Chief Medical Officer · since Mar 17, 2025
10% owners 1
- InnoCare Pharma Inc. (entity) · since Oct 7, 2025
Changes in the last 10 years (39)
| Sep 1, 2026 | Christy J. Oliger became a director |
| May 11, 2026 | The company announced the departure of Tomas Kiselak from the board in an SEC filing |
| Oct 14, 2025 | Sr One Capital Management, LLC reported in an SEC filing no longer being a 10% owner |
| Oct 14, 2025 | Simeon George reported in an SEC filing no longer being a 10% owner |
| Oct 7, 2025 | InnoCare Pharma Inc. became a 10% owner |
| Jun 10, 2025 | The company announced the departure of Ting Xiao from the board in an SEC filing |
| Mar 17, 2025 | Lisa von Moltke became Head of Research and Development and Chief Medical Officer |
| Sep 18, 2024 | Zebra Aggregator, LP reported in an SEC filing no longer being a 10% owner |
| Sep 18, 2024 | Wellington Biomedical Innovation Master Investors (Cayman) I L.P. reported in an SEC filing no longer being a 10% owner |
| Sep 18, 2024 | Enavate Sciences GP, LLC reported in an SEC filing no longer being a 10% owner |
| Sep 16, 2024 | Tomas Kiselak no longer listed as a 10% owner in SEC filings |
| Sep 16, 2024 | Peter Evan Harwin no longer listed as a 10% owner in SEC filings |
| Sep 16, 2024 | Fairmount Healthcare Fund II L.P. no longer listed as a 10% owner in SEC filings |
| Sep 16, 2024 | Fairmount Funds Management LLC no longer listed as a 10% owner in SEC filings |
| Sep 12, 2024 | Zebra Aggregator, LP became a 10% owner |
| Sep 12, 2024 | Wellington Biomedical Innovation Master Investors (Cayman) I L.P. became a 10% owner |
| Sep 12, 2024 | Tomas Kiselak became a director |
| Sep 12, 2024 | Tomas Kiselak became a 10% owner |
| Sep 12, 2024 | Ting Xiao became a director |
| Sep 12, 2024 | Sr One Capital Management, LLC became a 10% owner |
| Sep 12, 2024 | Simeon George became a 10% owner |
| Sep 12, 2024 | Peter Evan Harwin became a director |
| Sep 12, 2024 | Peter Evan Harwin became a 10% owner |
| Sep 12, 2024 | Patrick G Enright became a director |
| Sep 12, 2024 | Patricia L Allen became a director |
| Sep 12, 2024 | Orlando Oliveira became Chief Commercial Officer |
| Sep 12, 2024 | Leon O Moulder Jr became a director |
| Sep 12, 2024 | Leon O Moulder Jr became Chief Executive Officer |
| Sep 12, 2024 | Joseph L Farmer became President and Chief Operating Officer |
| Sep 12, 2024 | John J Orloff became a director |
| Sep 12, 2024 | Jennifer A. Fox became Chief Business Officer and Chief Financial Officer |
| Sep 12, 2024 | Jason Raleigh Nunn became a director |
| Sep 12, 2024 | James P Boylan became a director |
| Sep 12, 2024 | Hongbo Lu became a director |
| Sep 12, 2024 | Fairmount Healthcare Fund II L.P. became a director |
| Sep 12, 2024 | Fairmount Healthcare Fund II L.P. became a 10% owner |
| Sep 12, 2024 | Fairmount Funds Management LLC became a director |
| Sep 12, 2024 | Fairmount Funds Management LLC became a 10% owner |
| Sep 12, 2024 | Enavate Sciences GP, LLC became a 10% owner |
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
ZBIO Proposed Insider Sales (Form 144)
Latest: 2026-08-19
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
1 filing
· $31.9M notice value
· 1 unique filer
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
Top 90-day filers:
Zebra Aggregator, LP (1, $31.9M)
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-08-19 | Zebra Aggregator, LP | Affiliate | 1,000,000 | $31.91M | 2026-08-19 | J.P. Morgan Securities LLC | — | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
48 ETFs hold ZBIO
25 shown · $145.12M total exposure · 0.04% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $31.5M | — | 2026-09-30 |
| 2 | XBI State Street® SPDR® S&P® Biotech ETF | SPDR (State Street) | 0.29% | $29.6M | $10.4B | 2026-10-23 |
| 3 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.03% | $24.3M | $74.6B | 2026-10-23 |
| 4 | VXF Vanguard Extended Market ETF | Vanguard | 0.01% | $13.9M | — | 2026-09-30 |
| 5 | IWO iShares Russell 2000 Growth ETF | iShares (BlackRock) | 0.07% | $9.0M | $13.7B | 2026-10-23 |
| 6 | IBB iShares Biotechnology ETF | iShares (BlackRock) | 0.07% | $7.0M | $10.7B | 2026-10-23 |
| 7 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.03% | $5.7M | — | 2026-09-30 |
| 8 | FYC First Trust Small Cap Growth AlphaDEX® Fund | First Trust | 0.26% | $3.4M | $1.3B | 2026-10-23 |
| 9 | IWC iShares Micro-Cap ETF | iShares (BlackRock) | 0.24% | $3.0M | $1.2B | 2026-10-23 |
| 10 | SCHA Schwab U.S. Small-Cap ETF | Nport | 0.01% | $2.5M | — | 2026-05-31 |
| 11 | VHT Vanguard Health Care ETF | Vanguard | 0.01% | $2.2M | — | 2026-09-30 |
| 12 | FFSM Fidelity Fundamental Small-Mid Cap ETF | Nport | 0.14% | $2.1M | — | 2026-07-31 |
| 13 | ITOT iShares Core S&P Total U.S. Stock Market ETF | iShares (BlackRock) | 0.00% | $1.6M | $96.5B | 2026-10-23 |
| 14 | VFMO Vanguard U.S. Momentum Factor ETF | Vanguard | 0.07% | $1.3M | — | 2026-10-23 |
| 15 | LABU Direxion Daily S&P Biotech Bull 3X ETF | Direxion | 0.20% | $1.2M | — | 2026-10-26 |
| 16 | DWAS Invesco Dorsey Wright SmallCap Momentum ETF | Nport | 0.26% | $1.1M | — | 2026-05-31 |
| 17 | VTWG Vanguard Russell 2000 Growth ETF | Vanguard | 0.06% | $1.1M | — | 2026-09-30 |
| 18 | SBIO ALPS Medical Breakthroughs ETF | Nport | 0.63% | $1.0M | — | 2026-05-31 |
| 19 | FYX First Trust Small Cap Core AlphaDEX® Fund | First Trust | 0.06% | $840,789 | $1.4B | 2026-10-23 |
| 20 | PKW Invesco BuyBack Achievers ETF | Invesco | 0.04% | $645,740 | — | 2026-10-24 |
| 21 | GSSC Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF | Goldman | 0.05% | $532,187 | $1.0B | 2026-10-23 |
| 22 | BBC Virtus Biotech Clinical Trials Etf | Nport | 1.06% | $493,514 | — | 2026-07-31 |
| 23 | RSSL Global X Russell 2000 ETF | Global X | 0.03% | $473,458 | — | 2026-10-26 |
| 24 | ONEQ Fidelity Nasdaq Composite Index ETF | Fidelity | 0.00% | $461,680 | $10.7B | 2026-10-23 |
| 25 | FHLC Fidelity MSCI Health Care Index ETF | Fidelity | 0.01% | $360,192 | $3.8B | 2026-10-23 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-8.98
TTM Revenue
$1.00M
TTM Net Income
$-484.38M
TTM Op. Cash Flow
$-225.97M
Quarterly figures (8 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q2 '26 | 2026-06-30 | $1.00M | $-111.46M | $-1.77 | $-57.24M |
| Q1 '26 | 2026-03-31 | — | $-80.99M | $-1.46 | $-75.20M |
| Q4 '25 | 2025-12-31 | $0.00 | $-240.44M | $-5.17 | $-52.41M |
| Q3 '25 | 2025-09-30 | — | $-51.50M | $-1.22 | $-41.12M |
| Q2 '25 | 2025-06-30 | $0.00 | $-52.22M | $-1.25 | $-41.74M |
| Q1 '25 | 2025-03-31 | $10.00M | $-33.57M | $-0.80 | $-37.05M |
| Q4 '24 | 2024-12-31 | $5.00M | $-52.60M | $16.94 | $-38.55M |
| Q3 '24 | 2024-09-30 | — | $-38.61M | $-5.02 | $-31.06M |
Q2 2026 • period ending 2026-06-30 • filed 2026-08-13
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
5.90
P/S
1457.28
EV/EBITDA
—
EV/Sales
1557.72
ROE
-196.0%
ROA
-69.0%
Div Yield
0.00%
FCF Yield
-15.51%
Debt/Equity
1.20
Current Ratio
—
Market Cap
$1.46B
as of 2026-10-26
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
11.94M
SI % of Float
38.32%
Days to Cover
15.48
Short Vol Ratio
57.2%
Free Float
31.16M
Float %
47.8%
Short interest 2026-09-30 • Short volume 2026-10-26 • Float 2026-08-21